secwatch / observer
8-K filed May 28, 2025, 7:59 PM ET ticker ADVB CIK 0001941029
leadership confidence high sentiment neutral materiality 0.25

Advanced Biomed board member Dr. Hung To Pau resigns, Steven I-Fang Cheng appointed

Advanced Biomed Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Hung To Pau

Director
ADVB · Advanced Biomed Inc.
Effective
2025-05-23
Successor
Steven I-Fang Cheng
Filed
May 28, 2025, 7:59 PM ET
On May 23, 2025, the Board of Directors of Advanced Biomed Inc. (the “Company”) accepted the resignation of Dr. Hung To Pau from the Board of Directors for personal reasons.
Appointed

Steven I-Fang Cheng

Member of the Board of Directors
ADVB · Advanced Biomed Inc.
Effective
2025-05-23
Filed
May 28, 2025, 7:59 PM ET
On May 23, 2025, the Board of Directors of the Company appointed Mr. Steven I-Fang Cheng as a member of the Board of Director, effective May 23, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Hung To Pau resigned as Director at Advanced Biomed Inc..

Action
resigned
Role
Director
Exact text from the filing
On May 23, 2025, the Board of Directors of Advanced Biomed Inc. (the “Company”) accepted the resignation of Dr. Hung To Pau from the Board of Directors for personal reasons.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Steven I-Fang Cheng was appointed as Member of the Board of Directors at Advanced Biomed Inc..

Action
appointed
Role
Member of the Board of Directors
Exact text from the filing
On May 23, 2025, the Board of Directors of the Company appointed Mr. Steven I-Fang Cheng as a member of the Board of Director, effective May 23, 2025.
View on SEC.gov

Advanced Biomed Inc. filing history →

Source: SEC EDGAR
accession 0001213900-25-048271
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.